Gynecologic Oncologist, parent, advocate for patients with Gyn cancer. Opinions are mine not NYU Langone School of Medicine
Joined March 2013
- Tweets1.4K
- Following601
- Followers1.4K
- Likes1K
Bhavana Pothuri retweeted
The TroFuse-005 numbers: median OS 19.0 vs 12.1 months (HR 0.68), median PFS 7.2 vs 3.9 months (HR 0.59), response 35.1% vs 17.3%. The FDA set a June 15, 2027 action date with priority review.
So honored as GOG PI to mentor @mdslightfoot on this practice changing trial. What an amazing win for pts w/ adv/rec #EC. The 1st ph3 ADC trial in #EC and 1st phase 3 TROP2 ADC trial in #gynca. Grateful to @LorussoDomenica & @merck for colloboration. @myESMO @ASCO @SGO_org @GOG
🚺 Phase III TroFuse-005 results show that sacituzumab tirumotecan significantly improved progression-free and overall survival vs standard chemotherapy in previously treated advanced or recurrent #EndometrialCancer.
▪️@mdslightfoot & @BPothuri | #ESMO26
ascopost.com/news/october-20…
Bhavana Pothuri retweeted
amen
Unnecessary administrative burden shouldn't stand between patients & progress.
ASCO & @myESMO have issued a new joint consensus statement in @JCO_OA & @esmo_open exploring how updated ICH E6(R3) guidelines can help streamline clinical trials.
Read more: bit.ly/4ijgGj9
Bhavana Pothuri retweeted
Joyce Liu, MD, MPH, takes the stage at the Presidential Symposium III as a discussant on results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study, evaluating sacituzumab tirumotecan in patients with previously treated advanced or recurrent endometrial cancer. #ESMO26
Bhavana Pothuri retweeted
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results From the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study
🔬 Phase 3 (n=776): TROP2-directed ADC sacituzumab tirumotecan vs physician’s choice (doxorubicin or paclitaxel) in advanced/recurrent endometrial cancer after platinum and anti-PD-(L)1. Dual primary endpoints: PFS and OS.
➡️ Median PFS 7.2 vs 3.9 mo; HR 0.59 (0.50–0.70)
➡️ Median OS 19.0 vs 12.1 mo; HR 0.68 (0.55–0.84)
➡️ ORR 35.1% vs 17.3%; grade ≥3 TRAEs 54.4% vs 41.4%
✅ Authors: significant PFS, OS and ORR improvement with manageable safety, supporting sac-TMT as a new treatment option in this population. #EndometrialCancer
🎙️ Domenica Lorusso
(4Sight Made from Abstracts publicly available at the ESMO website)
Bhavana Pothuri retweeted
Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study by Domenica Lorusso (Italy) #ESMO2026
Bhavana Pothuri retweeted
TroFuse-005/GOG-3095 (Lorusso, #ESMO26): Options after carbo/paclitaxel/ICI in recurrent endometrial cancer are limited and poor. Sac-TMT is the first TOP1 ADC to read out positive in phase 3: PFS HR 0.59 (7.2 vs 3.9 mo), ORR 35% vs 17%, plus an OS benefit. That is clinically meaningful and warrants use.
The tox is a concern. Stomatitis 57% (mostly low grade, needs prophylactic steroid mouthwash), ocular 31%, anemia 71%. Requires aggressive counseling and mitigation. Several other ADCs are in phase 3, and I hope they match this efficacy with better tolerability. Time will tell. @myESMO
Bhavana Pothuri retweeted
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial - The Lancet thelancet.com/journals/lance… – at Kakkodi, India
Bhavana Pothuri retweeted
If you are an oncologist who cares for women with ovarian cancer please consider participating in the physician survey for the Lancet Commission on Oncology. It is long but the responses will be critical as we draft a document that we hope guides policy and research funding in the future.
We need your participation!
The Lancet Commission on #OvarianCancer is an international forum of experts on ovarian cancer:
🔍 Screening
🛡️ Prevention
🧬 Biology
💊 Therapeutics
📈 Survivorship
👤 Patient experience
Over 3 years, it will produce a Commission report to guide future policy.
More info: bit.ly/4B5Fl3k
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @Suvidyasingh20 @ohadfeld
Bhavana Pothuri retweeted
sac-TMT reduced the risk of disease progression or death by 41% and the risk of death by 32% vs chemo in advanced or recurrent endometrial cancer. Watch @BPothuri discuss TroFuse-005 trial👉 ow.ly/szAO51016ck #ESMO26 #EndometrialCancer #CancerResearch
Bhavana Pothuri retweeted
Bhavana Pothuri, MD (@nyulangone @Perlmutter_CC) discusses phase 3 TroFuse-005 data from #ESMO26, where sac-TMT improved PFS and OS vs chemotherapy in #EndometrialCancer.
🎥 WATCH: targetedonc.com/view/trofuse…
#GynOnc #Oncology #CancerTreatment | @BPothuri
Bhavana Pothuri retweeted
Congrats to Dr. Elizabeth Swisher on her election to @theNAMedicine! Her pioneering work in hereditary ovarian cancer and PARP inhibitors has transformed care and improved outcomes for women around the world. bit.ly/4z1AZIV
Bhavana Pothuri retweeted
This month’s Protocol Support Committee Column discusses RECIST 1.1 Documentation. Accurate RECIST 1.1 documentation supports protocol compliance, timely treatment decisions, and study data integrity. Read more: ow.ly/126550ZXkKB
So proud of my star NP @Kathleen Lutz who is program chair for this meeting! Congrats on a great meeting educating Allied health professionals. @nyulangone @Perlmutter_CC
Day one of the 2026 Allied Health Professionals Meeting is in the books! Attendees gathered to explore advances in gynecologic oncology, share ideas, and strengthen connections across the care team. The day wrapped up with an opening reception and great conversations. #SGOMtg
Bhavana Pothuri retweeted
Screening at 45, colonoscopy and stool-based tests up front, and blood-based tests entering the mix.
Dr. Aasma Shaukat (@AasmaShaukatMD) previews her Emily Couric Lectureship at @AmCollegeGastro 🎥⤵️
Bhavana Pothuri retweeted
Early data on VS-7375, @VerastemOncolog KRASG12D inhibitor in 2nd line and beyond #PancreaticCancer
50% ORR in 2nd line, 35% in 3rd/4th line
6mo OS of 80%
Proceeding with Phase 3 randomized trial in 1st line pancreatic (VS-7375 +EGFRi v VS-7375 + chemo)
investor.verastem.com/news-r…
Bhavana Pothuri retweeted
Out now in Nature Medicine: a health-system-scale cachexia atlas (52K patients) that describes and predicts outcomes, with prospective risk models for lung, colorectal, and prostate cancer. Congrats to @EdReznik for a landmark paper for the field. nature.com/articles/s41591-0…
Yes @avash22 you are spot on for those diagnosed with cancer! More provocative is should general population based #genetictesting be utilized? With NGS costs decreasing this is where the field is heading. We have a pilot study evaluating this- stay tuned.
Bhavana Pothuri retweeted
What are plastics doing to our health?
In a @TEDx talk, Dr. Leonardo Trasande from @nyulangone examines the evidence linking chemicals used in plastics to human health risks—and where science and policy can make a difference.
Watch the full talk ⤵️ youtube.com/watch?v=2pwaWFA4…
Congratulations Catherine! So well deserved! @Perlmutter_CC
Congratulations to Catherine S. Diefenbach, MD, on her greatly deserved promotion to Professor of Medicine. As Director of Hematology Translational Research and Director of the Clinical Lymphoma Program at the Perlmutter Cancer Center, Dr. Diefenbach is dedicated to providing the best possible care for individuals diagnosed with lymphoma — combining cutting-edge, patient-focused, and translational research with personalized clinical care.
#Exceptionalism #Leadership #FacultyAchievement #TranslationalResearch #Lymphoma
